Seaport downgrades Energy Recovery stock rating on Middle East risks

Energy Recovery reported Q2 2026 revenue of $11.99 million, missing the $19.97 million consensus by about 40%, while adjusted EPS loss of $0.03 was worse than the expected $0.01 loss. Middle East conflict-related delays have stalled desalination project financing and execution, prompting management to withdraw desalination guidance and Seaport Global to downgrade ERII to Neutral from Buy. The stock is down 44% year-to-date at $7.55, near its $7.25 52-week low; B.Riley cut its price target to $8 from $10 despite retaining a Buy rating.

Analysis

ERII is no longer principally a desalination-technology valuation; it is an execution-duration and customer-financing-risk story. With core projects deferred rather than cancelled, reported revenue can remain depressed well beyond the point at which Middle East headlines improve, because procurement restart, EPC mobilization, and acceptance testing create a multi-quarter lag. The withdrawal of segment guidance also raises the discount rate investors should apply to backlog and pipeline, while negative EBITDA reduces the market’s tolerance for further schedule slippage.

The key near-term issue is liquidity and fixed-cost absorption, not whether the technology retains a theoretical efficiency advantage. At the current revenue run-rate, another two to three quarters of weak project conversion could force cost actions that impair the company’s ability to service a simultaneous project restart. A new CEO is a potential 1-3 month sentiment catalyst, but a credible rerating requires independently observable evidence: disclosed order intake, funded customer milestones, restored guidance, and sequential EBITDA improvement.

Consensus may overstate the value of apparent cheapness near the prior low: small-cap industrials with withdrawn guidance often establish new lows when estimates reset again, especially if the addressable-market case for wastewater remains unproven. Conversely, the asymmetric bull case is an asset-light licensing model with substantial operating leverage if delayed desalination awards convert; that is a 6-18 month optionality thesis, not a reason to underwrite the next quarter. There is no clean public-company peer with equivalent desalination exposure, limiting a fundamental pair-trade hedge.

Key Decisions for Investors

• Maintain an underweight/avoid ERII over the next 1-3 months; do not buy solely on the drawdown. Reassess after the next earnings release only if order intake or funded backlog is disclosed and management provides a measurable path to positive EBITDA.
• For existing long exposure, use a close below the 52-week-low area as a risk trigger rather than averaging down. The thesis is falsified by another material revenue miss, further guidance opacity, or cash-burn acceleration; upside validation is a CEO appointment paired with specific 2027 desalination conversion milestones.
• Do not initiate a directional short at current depressed levels without borrow/liquidity confirmation: the stock is vulnerable to sharp relief rallies on a CEO announcement or a single large project award. If short exposure is required, size it as a catalyst trade into the next results period and cap risk with calls.
• Place an event-driven long watch alert, not a recommendation, for a documented restart of Middle East project financing or a major contract award. A position would be warranted only after evidence that revenue conversion is resuming; then target a 6-18 month recovery trade, with size constrained by customer and regional concentration.